Antibe Therapeutics (CVE:ATE) (OTCMKTS:ATBPF) released a shareholder update Tuesday, which highlighted its annual general and special meeting, noting all resolutions outlined in the management information circular were approved.
The firm noted shareholders elected a number of directors: Roderick Flower, Amal Khouri, Daniel Legault, Walt Macnee, John Wallace and Yung Wu.
Shareholders also approved the reappointment of Ernst & Young LLP, Chartered Accountants, as Antibe's auditor, as well as an amendment to the restricted share unit plan.
Antibe's lead drug, ATB-346, targets acute and chronic pain associated with osteoarthritis and its Phase 2B dose-ranging, efficacy study for the drug remains on track.
The firm is developing a platform of unique drugs to prevent gastrointestinal damage and bleeding caused by using non-steroidal anti-inflammatory drugs known as NSAIDs, which are currently the primary therapy for pain relief.
Shares of Antibe were at C$0.32 on Tuesday.
Contact Katie Lewis at [email protected]